Clinical Trials Directory

Trials / Completed

CompletedNCT03463226

Effects of Hormonal Anabolic Deficiency and Neurovascular Alterations on Mortality in Male Patients With Heart Failure

Hormonal Anabolic Deficiency Associated With Neurovascular Alterations Predict Poor Prognosis in Male Patients With Heart Failure

Status
Completed
Phase
Study type
Observational
Enrollment
169 (actual)
Sponsor
University of Sao Paulo General Hospital · Academic / Other
Sex
Male
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Heart failure (HF) has been associated with chronic deleterious effects on skeletal muscle, endocrine system, vasculature and sympathetic nervous system. These alterations have a significant impact on quality of life, leading to a reduction in functional capacity and limited symptoms, which involve dyspnea and fatigue. The investigators tested the hypothesis that hormonal anabolic deficiency associated with neurovascular alterations may worsen the prognosis of patients with heart failure.

Detailed description

One hundred and fifty six patients have been enrolled so far. Methods were as described below: * Muscle sympathetic nerve activity (MSNA) was directly recorded from the peroneal nerve using the microneurography technique ; * All patients underwent symptom-limited cardiopulmonary exercise test performed on a cycle ergometer, using a ramp protocol with workload increments of 5 or 10 Watts per minute; * Body composition measurements were performed using dual-energy X-ray absorptiometry (DXA); * Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts; * Blood samples were drawn in the morning after 12h overnight fasting. The laboratory tests included B-type natriuretic peptide (BNP; pg/mL) plasma level, serum sodium (mEq/L), serum potassium (mEq/L), creatinine (mg/dL), haemoglobin level (g/dL), high-sensitivity C-reactive protein (CRP; mg/L), lipid profile (triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein; mg/dL), and fasting glucose (mg/dL). Blood sample to assess hormone plasma levels were also drawn at the same time: total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin-like growth factor 1 (IGF1).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCardiopulmonary exercise testOxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
DIAGNOSTIC_TESTMuscle Sympathetic Nerve ActivityMultiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
DIAGNOSTIC_TESTDual-energy X-ray absorptiometryDual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
DIAGNOSTIC_TESTVenous occlusion plethysmographyVenous occlusion plethysmography was used to assess non-invasively blood flow.
DIAGNOSTIC_TESTBlood sample collectionBlood samples were drawn in the morning after 12h overnight fasting.
DIAGNOSTIC_TESTDynamometers for Handgrip StrengthMuscle strength was assessed by handgrip dynamometer using the mean value of three attempts.

Timeline

Start date
2016-06-30
Primary completion
2020-03-23
Completion
2020-12-30
First posted
2018-03-13
Last updated
2021-05-03

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT03463226. Inclusion in this directory is not an endorsement.